MENU
Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 04, 2019
Bausch Health (BHC, $26.30) beats Q3 revenue expectations; hikes full-year sales guidance

Bausch Health (BHC, $26.30) beats Q3 revenue expectations; hikes full-year sales guidance

Bausch Health posted third-quarter revenue that surpassed analysts’ expectations. The company also boosted its revenue guidance.

In the third quarter, the pharmaceutical company’s revenue increased to $2.21 billion ( from $2.14 billion a year earlier), beating analysts’ estimate of $2.16 billion.

Bausch reported a loss of -$49 million, or -14 cents a share - compared to a loss of -$350 million, or -$1 a share in the year-ago quarter.

Adjusted net income for the quarter came in at $425 million, up from $403 million a year earlier.

Looking ahead, Bausch Health now expects a revenue range of $8.475 billion to $8.625 billion for the full-year 2019, up from its previous guidance of $8.4 billion to $8.6 billion.

CEO Joseph Papa emphasized on the strength of the company's long-standing brands, Xifaxan, BioTrue Oneday and Bausch + Lomb Ultra, as well as successful performances of newer products, such as Lumify and Thermage. Papa is also optimistic about their newest  dermatology product Duobrii.

 

Related Ticker: BHC

BHC's RSI Indicator is staying in oversold zone for 1 day

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BHC advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .

BHC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BHC as a result. In of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BHC turned negative on March 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 50-day moving average for BHC moved below the 200-day moving average on March 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BHC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BHC entered a downward trend on February 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (25.926). P/E Ratio (12.810) is within average values for comparable stocks, (64.738). BHC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.963). BHC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (0.197) is also within normal values, averaging (113.698).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BHC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.89B. The market cap for tickers in the group ranges from 2.12K to 64.54B. MKKGY holds the highest valuation in this group at 64.54B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -1%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was -0%. IXHL experienced the highest price growth at 2,659%, while LVRLF experienced the biggest fall at -80%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -41%. For the same stocks of the Industry, the average monthly volume growth was -70% and the average quarterly volume growth was -78%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 66
Price Growth Rating: 60
SMR Rating: 79
Profit Risk Rating: 91
Seasonality Score: -12 (-100 ... +100)
View a ticker or compare two or three
BHC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. BHC showed earnings on February 18, 2026. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceutical products

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
2150 Saint Elzear Boulvard West
Phone
+1 514 744-6792
Employees
20270
Web
https://www.bauschhealth.com
Interact to see
Advertisement
Financial Learning Models (FLMs) and machine learning (ML) to operate at unprecedented speeds. These agents, now optimized for 5-minute (M5) timeframes, have demonstrated extraordinary annualized returns, with the top agent exceeding +160%.
AI-Driven Market Insights A.I.dvisor’s latest analysis compares SPY and VOO, two leading ETFs, revealing near-identical year-to-date (YTD) gains of 9.82% for SPY and 9.87% for VOO, a 99% parity.
Tickeron, a leader in AI-driven financial technology, today announced the launch of its advanced AI Trading Agents. These innovative brokerage agents provide real-time trading signals powered by machine learning, utilizing tick-level brokerage data and precise trade amounts across 5-, 15-, and 60-minute timeframes.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technology, today announced groundbreaking results from its AI Trading Agents, showcasing exceptional performance in real-time trading signals powered by machine learning. Utilizing tick-level brokerage data and precise trade amounts, these agents operate on 5-, 15-, and 60-minute timeframes to provide traders with actionable insights in volatile markets.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technology, today announced the launch of its advanced AI Trading Agents. These cutting-edge brokerage agents deliver real-time trading signals powered by machine learning, leveraging tick-level brokerage data and precise trade amounts across 5-, 15-, and 60-minute timeframes. Designed to empower traders with superior insights, the agents have demonstrated exceptional performance, including annualized returns as high as 82%.
#artificial_intelligence
The financial markets have undergone a profound transformation in recent years, driven by the integration of artificial intelligence (AI) into trading strategies. As a financial analyst, writer, and AI specialist, one observes that AI trading agents represent a pinnacle of this evolution, blending machine learning algorithms with real-time data analysis to execute trades with unprecedented precision.
#artificial_intelligence
AI trading represents a revolutionary shift in how financial markets operate, combining artificial intelligence, machine learning, and sophisticated algorithmic trading strategies to execute trades with unprecedented precision and speed.
#artificial_intelligence
Tickeron, a leader in AI-driven financial tools, today announced exceptional trading results from its AI Trading Agent focused on Hubbell Incorporated (HUBB). The agent, operating on a 5-minute timeframe, delivered a +105% annualized return, starting from an initial balance of $100,000.
#artificial_intelligence
Tickeron, a leader in AI-driven financial technology, today announced the launch of its advanced AI Trading Agents, delivering real-time trading signals and sophisticated money management for retail and institutional traders. Powered by Financial Learning Models (FLMs) and machine learning, these agents operate across 5-, 15-, and 60-minute timeframes, achieving annualized returns of up to 145% on select portfolios.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technology, today announced the exceptional performance of its AI Trading Agents, achieving annualized returns of up to 162%, profitable trade percentages as high as 90.51%, and a robust profit factor across multiple assets.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technology, proudly announces the exceptional performance of its AI Trading Agents, delivering annualized returns of up to 188% on a 5-minute timeframe.
#artificial_intelligence
Tickeron, a leader in AI-driven financial tools, today announced the launch of its advanced Pattern Search Engine (PSE), a revolutionary platform that scans 39 distinct trading patterns across stocks, penny stocks, ETFs, crypto, and forex.
#artificial_intelligence
AI trading bots represent the pinnacle of financial technology innovation, transforming how traders and investors interact with global markets.
#artificial_intelligence
As a financial analyst, writer, and AI specialist, I've always pushed for innovations that merge artificial intelligence with actionable trading tools. In the fast-paced world of modern markets, where volatility demands quick decisions, Tickeron's new "My Trades Aggregator (from AI Robots Followed)" aggregator stands out as a revolutionary feature.
#artificial_intelligence#trading
Tickeron, a leading provider of AI-driven trading solutions, is thrilled to announce the exceptional performance of its AI Trading Agents, delivering outstanding results across multiple high-profile stocks.
#artificial_intelligence
Tickeron, a leader in AI-driven financial technologies, today announced groundbreaking results from its AI Crypto Trading Virtual Agents. These innovative tools provide real-time trading signals, integrated money management, and customizable balances, all powered by advanced machine learning algorithms operating on 5-, 15-, and 60-minute timeframes.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technologies, today announced the launch of its advanced AI Trading Brokerage Agents. These cutting-edge tools deliver real-time trading signals powered by machine learning, utilizing tick-level brokerage data and precise trade amounts across 5-, 15-, and 60-minute timeframes.
#artificial_intelligence
This remarkable rally represents far more than typical market volatility – it signals a fundamental transformation in investor sentiment toward AI connectivity infrastructure and the critical role of semiconductor-based solutions in enabling next-generation artificial intelligence systems
Tickeron, a leader in AI-driven financial tools, today announced the launch of its comprehensive subscription package combining AI Trading Robots for cryptocurrencies with Real-Time Patterns (RTP) analysis.
#artificial_intelligence
Kinross Gold Corporation (KGC), a leading Canada-based gold producer, yielded approximately 2.1 million gold equivalent ounces in 2024.
#artificial_intelligence